Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu vaccine contracts

Executive Summary

Five drug manufacturers received five-year contracts totaling roughly $1 bil. to accelerate development and production of new cell-based vaccine technologies within the U.S., HHS announces May 4. Solvay received the largest contract ($298.6 mil.) to develop and test vaccines, as well as to develop a master plan to manufacture, formulate, fill and package annual and pandemic vaccines. GlaxoSmithKline received $274.8 mil. for clinical programs for a trivalent seasonal flu vaccine and an H5N1 vaccine. Novartis received $220.5 mil. to augment vaccine research efforts and to aid in establishing a U.S.-based vaccine manufacturing facility. MedImmune received $169.5 mil. to develop cell-based seasonal and pandemic vaccines using technology underlying FluMist. Computer Sciences Corp.'s DynPort Vaccine Co., which is working with Baxter on seasonal and pandemic vaccines, also received an incremental award of $41 mil. toward a pending $242.6 mil. contract...

You may also be interested in...



No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

David Now Goliath? Made In China PD-1s Sought After By Multinationals

From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.

How Heads Of Indian Firms Rallied To Sustain Global Supplies Amid COVID-19

The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel